ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer.
Eric Van CutsemGilles ManceauRona YaegerTakayuki YoshinoAxel GrotheyEvaristo MaielloElena ElezJeroen DekervelPaul J RossAna Ruiz-CasadoJanet GrahamTakeshi KatoJose Carlos RuffinelliThierry AndréEdith Carrière RousselIsabelle KlauckMélanie GrocJean-Claude VedovatoJosep TaberneroPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
-mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421).